Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia

被引:201
作者
Warkentin, Theodore E.
Sheppard, Jo-Ann I.
Sigouin, Christopher S.
KohImann, Thomas
Eichler, Petra
Greinacher, Andreas
机构
[1] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada
[2] McMaster Univ, Dept Med, Hamilton, ON, Canada
[3] Ernst Moritz Arndt Univ Greifswald, Inst Community Med, Greifswald, Germany
[4] Ernst Moritz Arndt Univ Greifswald, Dept Transfus Med & Immunol, Greifswald, Germany
关键词
D O I
10.1182/blood-2005-11-012450
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heparin-induced thrombocytopenla (HIT) is caused by antibodies against a "self" protein-platelet factor 4-bound to heparin. We observed an overrepresentation of the female gender in 290 patients who developed HIT after cardiac or orthopedic surgery compared with the representation found in national databases (study 1). Therefore, we investigated gender imbalance in HIT by logistic regression analysis of a randomized controlled trial of unfractionated heparin (UFH) and lowmolecular-weight heparin (LMWH) (study 2), and we analyzed individual patient data from 7 prospective studies comparing HIT frequency between UFH and LMWH, evaluating effects of gender, heparin (UFH vs LMWH), and patient type (surgical vs medical) (study 3). All 3 studies showed female overrepresentation, which for study 3 was a common odds ratio (OR) of 2.37 (95% confidence interval [95% CI], 1.37-4.09; P = .0015). Study 3 also showed an interaction between gender, heparin, and patient type. Although UFH was more likely than LMWH to cause HIT (P < .0001), this effect was predominantly seen in women compared with men (common OR, 9.22 vs 1.83; P = .020) and in surgical patients compared with medical patients (common OR, 13.93 vs 1.75; P = .005). We conclude that females are at greater risk for HIT and that using LMWH to prevent HIT may have greatest absolute benefit in females undergoing surgical thromboprophylaxis.
引用
收藏
页码:2937 / 2941
页数:5
相关论文
共 46 条
[1]   How I treat heparin-induced thrombocytopenia and thrombosis [J].
Alving, BM .
BLOOD, 2003, 101 (01) :31-37
[2]  
AMIRAL J, 1992, THROMB HAEMOSTASIS, V68, P95
[3]  
Arepally Gowthami, 2002, Autoimmunity Reviews, V1, P125, DOI 10.1016/S1568-9972(02)00031-9
[4]  
*BUND QUAL, 2006, TOT TEP KOX
[5]  
*BUND QUAL, 2006, KNIET TEP
[6]   Potential role of platelet FcγRIIA in collagen-mediated platelet activation associated with atherothrombosis [J].
Calverley, DC ;
Brass, E ;
Hacker, MR ;
Tsao-Wei, DD ;
Espina, BM ;
Pullarkat, VA ;
Hodis, HN ;
Groshen, S .
ATHEROSCLEROSIS, 2002, 164 (02) :261-267
[7]   Heparin-induced thrombocytopenia:: New insights into the impact of the FcγRIIa-R-H131 polymorphism [J].
Carlsson, LE ;
Santoso, S ;
Baurichter, G ;
Kroll, H ;
Papenberg, S ;
Eichler, P ;
Westerdaal, NAC ;
Kiefel, V ;
van de Winkel, JGJ ;
Greinacher, A .
BLOOD, 1998, 92 (05) :1526-1531
[8]   Medical progress: Immune thrombocytopenic purpura. [J].
Cines, DB ;
Blanchette, VS .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (13) :995-1008
[9]   Activation of platelets by sera containing IgG1 heparin-dependent antibodies: An explanation for the predominance of the Fc gamma RIIa ''low responder'' (his(131)) gene in patients with heparin-induced thrombocytopenia [J].
Denomme, GA ;
Warkentin, TE ;
Horsewood, P ;
Sheppard, JAI ;
Warner, MN ;
Kelton, JG .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1997, 130 (03) :278-284
[10]   Dangerous potentials in medicamentous prophylaxis of thrombosis - Low molecular-weight heparins versus standard heparins. [J].
Ganzer, D ;
Gutezeit, A ;
Mayer, G .
ZEITSCHRIFT FUR ORTHOPADIE UND IHRE GRENZGEBIETE, 1999, 137 (05) :457-461